Universal Beteiligungs und Servicegesellschaft mbH Takes $1.95 Million Position in Progyny, Inc. (NASDAQ:PGNY)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Progyny, Inc. (NASDAQ:PGNY) in the 1st quarter, HoldingsChannel reports. The institutional investor purchased 87,088 shares of the company’s stock, valued at approximately $1,946,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Barclays PLC increased its stake in Progyny by 95.7% during the 4th quarter. Barclays PLC now owns 1,382,205 shares of the company’s stock valued at $23,843,000 after buying an additional 676,048 shares during the period. D. E. Shaw & Co. Inc. acquired a new stake in Progyny during the 4th quarter worth about $11,265,000. BNP Paribas Financial Markets acquired a new position in shares of Progyny in the 4th quarter valued at about $10,557,000. First Sabrepoint Capital Management LP acquired a new position in Progyny in the fourth quarter worth approximately $9,660,000. Finally, Voloridge Investment Management LLC grew its holdings in Progyny by 85.5% during the fourth quarter. Voloridge Investment Management LLC now owns 1,197,993 shares of the company’s stock valued at $20,665,000 after purchasing an additional 552,066 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Stock Up 2.9%

Shares of Progyny stock opened at $23.50 on Thursday. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $28.99. The stock has a market cap of $2.01 billion, a P/E ratio of 41.23, a P/E/G ratio of 2.29 and a beta of 1.31. The business’s 50 day moving average is $22.02 and its 200-day moving average is $22.06.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.28). The company had revenue of $324.04 million for the quarter, compared to the consensus estimate of $307.86 million. Progyny had a return on equity of 10.90% and a net margin of 4.33%. The company’s revenue for the quarter was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 EPS. On average, sell-side analysts expect that Progyny, Inc. will post 0.6 EPS for the current year.

Insider Buying and Selling at Progyny

In related news, Director Cheryl Scott sold 2,675 shares of the business’s stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total transaction of $59,037.25. Following the transaction, the director directly owned 14,112 shares of the company’s stock, valued at approximately $311,451.84. The trade was a 15.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on PGNY. Truist Financial raised their price objective on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. Canaccord Genuity Group reduced their target price on Progyny from $23.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, May 12th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Leerink Partnrs raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 8th. Finally, Leerink Partners raised Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 price target for the company in a report on Tuesday, July 8th. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.82.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.